Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study Protocol Number DBI-201- Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis

NCT04152226 is registered in ClinicalTrials.gov with DermBiont, Inc. as lead sponsor.

NCT NCT04152226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04152226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study Protocol Number DBI-201- Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis
Lead sponsor
DermBiont, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2019
Completion date
April 30, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tinea pedis